- Home
- VRCA vs CCEL Comparison
VRCA vs CCEL Comparison
Compare VRCA & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRCA
- CCEL
- Stock Information
- Founded
- VRCA 2013
- CCEL 1989
- Country
- VRCA United States
- CCEL United States
- Employees
- VRCA N/A
- CCEL N/A
- Industry
- VRCA Biotechnology: Pharmaceutical Preparations
- CCEL Managed Health Care
- Sector
- VRCA Health Care
- CCEL Health Care
- Exchange
- VRCA Nasdaq
- CCEL Nasdaq
- Market Cap
- VRCA 32.7M
- CCEL 34.8M
- IPO Year
- VRCA 2018
- CCEL 1997
- Fundamental
- Price
- VRCA $4.54
- CCEL $4.09
- Analyst Decision
- VRCA Hold
- CCEL Hold
- Analyst Count
- VRCA 2
- CCEL 1
- Target Price
- VRCA N/A
- CCEL N/A
- AVG Volume (30 Days)
- VRCA 93.9K
- CCEL 4.9K
- Earning Date
- VRCA 11-14-2025
- CCEL 10-15-2025
- Dividend Yield
- VRCA N/A
- CCEL 9.88%
- EPS Growth
- VRCA N/A
- CCEL N/A
- EPS
- VRCA N/A
- CCEL N/A
- Revenue
- VRCA $30,829,000.00
- CCEL $31,747,500.00
- Revenue This Year
- VRCA $332.45
- CCEL $0.30
- Revenue Next Year
- VRCA $12.85
- CCEL N/A
- P/E Ratio
- VRCA N/A
- CCEL N/A
- Revenue Growth
- VRCA 234.73
- CCEL N/A
- 52 Week Low
- VRCA $3.28
- CCEL $4.00
- 52 Week High
- VRCA $13.60
- CCEL $9.10
- Technical
- Relative Strength Index (RSI)
- VRCA 61.74
- CCEL 36.84
- Support Level
- VRCA $3.64
- CCEL $4.00
- Resistance Level
- VRCA $4.02
- CCEL $4.12
- Average True Range (ATR)
- VRCA 0.31
- CCEL 0.10
- MACD
- VRCA 0.10
- CCEL -0.02
- Stochastic Oscillator
- VRCA 92.28
- CCEL 13.46
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.